These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
307 related items for PubMed ID: 31129452
1. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. Su Y, Li R, Ning X, Lin Z, Zhao X, Zhou J, Liu J, Jin Y, Yin Y. Eur J Med Chem; 2019 Sep 01; 177():32-46. PubMed ID: 31129452 [Abstract] [Full Text] [Related]
2. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities. Wang S, Zhang RH, Zhang H, Wang YC, Yang D, Zhao YL, Yan GY, Xu GB, Guan HY, Zhou YH, Cui DB, Liu T, Li YJ, Liao SG, Zhou M. Eur J Med Chem; 2021 Oct 15; 222():113573. PubMed ID: 34091209 [Abstract] [Full Text] [Related]
3. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors. Li R, Gong L, Sun J, Liang Z, He J, Huang J, Ning X, Song H, Li R, Zhang Q, Lin Z, Yin Y. Bioorg Chem; 2024 Mar 15; 144():107134. PubMed ID: 38237389 [Abstract] [Full Text] [Related]
4. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Wang R, Yu S, Zhao X, Chen Y, Yang B, Wu T, Hao C, Zhao D, Cheng M. Eur J Med Chem; 2020 Feb 15; 188():112024. PubMed ID: 31923858 [Abstract] [Full Text] [Related]
5. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y, Ma X. Bioorg Med Chem; 2017 Dec 15; 25(24):6313-6321. PubMed ID: 29102081 [Abstract] [Full Text] [Related]
7. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Wang L, Liu X, Duan Y, Li X, Zhao B, Wang C, Xiao Z, Zheng P, Tang Q, Zhu W. Chem Biol Drug Des; 2018 Jul 15; 92(1):1301-1314. PubMed ID: 29575727 [Abstract] [Full Text] [Related]
10. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors. Xie H, Lin X, Zhang Y, Tan F, Chi B, Peng Z, Dong W, An D. Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127459. PubMed ID: 32784087 [Abstract] [Full Text] [Related]
11. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents. Wang R, Chen Y, Zhao X, Yu S, Yang B, Wu T, Guo J, Hao C, Zhao D, Cheng M. Eur J Med Chem; 2019 Dec 01; 183():111716. PubMed ID: 31550660 [Abstract] [Full Text] [Related]
12. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. AboulWafa OM, Daabees HMG, Badawi WA. Bioorg Chem; 2020 Jun 01; 99():103798. PubMed ID: 32247112 [Abstract] [Full Text] [Related]
13. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF, Abdelhameid MK, Kassab AE, Kandeel MM. Eur J Med Chem; 2018 Jan 01; 143():1807-1825. PubMed ID: 29133058 [Abstract] [Full Text] [Related]
14. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents. Duan YC, Ma YC, Zhang E, Shi XJ, Wang MM, Ye XW, Liu HM. Eur J Med Chem; 2013 Apr 01; 62():11-9. PubMed ID: 23353743 [Abstract] [Full Text] [Related]
15. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB, Mehany ABM, Abdellatif KRA. Anticancer Agents Med Chem; 2017 Apr 01; 17(10):1389-1400. PubMed ID: 28270084 [Abstract] [Full Text] [Related]
16. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. Wei W, Feng Z, Liu Z, Li X, He H, Ran K, Shi Y, Zhu Y, Ye T, Gao C, Wang N, Yu L. Eur J Med Chem; 2022 Jan 15; 228():113978. PubMed ID: 34810020 [Abstract] [Full Text] [Related]
17. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. Xie R, Li Y, Tang P, Yuan Q. Eur J Med Chem; 2018 Jan 01; 143():320-333. PubMed ID: 29202397 [Abstract] [Full Text] [Related]
18. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Wang Y, Chen S, Hu G, Wang J, Gou W, Zuo D, Gu Y, Gong P, Zhai X. Eur J Med Chem; 2018 Jan 01; 143():123-136. PubMed ID: 29174809 [Abstract] [Full Text] [Related]
19. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. Chen H, Li R, Ning X, Zhao X, Jin Y, Yin Y. Eur J Med Chem; 2019 Sep 15; 178():141-153. PubMed ID: 31177074 [Abstract] [Full Text] [Related]
20. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study. Wang R, Zhao X, Yu S, Chen Y, Cui H, Wu T, Hao C, Zhao D, Cheng M. Bioorg Chem; 2020 Sep 15; 102():104092. PubMed ID: 32707280 [Abstract] [Full Text] [Related] Page: [Next] [New Search]